Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319566 | 0.88 | MAP4K4 (0.44) | MAP4K4PIK3CACYP11B1CYP11B2IMPDH2 | |
| SCHEMBL6317900 | 0.84 | IMPDH2 (0.52) | IMPDH2 | |
| SCHEMBL6315288 | 0.80 | PDGFRB (0.49) | PIK3CATNFGRM4NPSR1ADORA2A | |
| SCHEMBL6318862 | 0.80 | DHFR (0.56) | PIK3CATNFGRM4NPSR1ADORA2A | |
| SCHEMBL6313300 | 0.78 | ABCG2 (0.46) | PIK3CATNFSYKGRM4NPSR1 | |
| SCHEMBL6312017 | 0.78 | CA2 (0.46) | PIK3CATNFMEN1KMT2A | |
| SCHEMBL6321220 | 0.77 | ABCG2 (0.48) | MEN1KMT2A | |
| SCHEMBL6318945 | 0.76 | TNF (0.44) | PIK3CATNFMEN1KMT2AGRM4 | |
| SCHEMBL6312244 | 0.76 | CYP1A2 (0.52) | PIK3CATNFMEN1KMT2AADORA2A | |
| SCHEMBL4492804 | 0.75 | MAP4K4 (0.57) | MAP4K4CYP11B1CYP11B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | claimed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | MAP4K4 3243/4885PIK3CA 423/4885CYP11B1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.